Clinical Impact of New Data From EADV 2016
Source: Clinical Impact of New Data From EADV 2016*


Clinical Impact of New Data From EADV 2016

In this downloadable slideset, the most clinically significant data from the 25th EADV Congress for the practical management of patients with psoriatic disease is highlighted.
Format: Microsoft PowerPoint (.ppt)
File size: 2.45 MB
Date posted: 11/30/2016
  • Key Considerations for Using Biosimilars in IBD

    David T. Rubin MD - 6/6/2017    1 comment / Last Comment: 6/22/2017
    The role of biosimilars in the setting of IBD is growing. Here’s my take on some of the key things you need to consider when using these agents.
  • Biosimilars: Addressing Uncertainties With a New Drug Class

    Kenneth G. Saag MD, MSc - 3/13/2017    2 comments / Last Comment: 4/24/2017
    Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.
  • Post-ACR Update: New Developments That Could Affect Treatment of Psoriatic Arthritis

    Vinod Chandran MBBS, MD, DM, PhD - 2/6/2015    1 comment / Last Comment: 3/18/2015
    The 2014 American College of Rheumatology annual meeting provided us with new and promising data on the safety and efficacy of current and investigational agents. How soon will we have new treatment options for patients with PsA?
  • The End of Winter or a False Spring? Introduction of Biosimilars in a Rheumatology Practice

    William F. C. Rigby MD - 6/12/2017    
    What does the availability of biosimilar products mean in your approach to rheumatologic conditions?
  • Targeting IL-17 in Psoriatic Arthritis: Key Data From the 2016 ACR Meeting

    Arthur Kavanaugh MD - 2/1/2017    1 comment / Last Comment: 2/2/2017
    The 2016 American College of Rheumatology annual meeting gave us promising data on agents targeting IL-17 in psoriatic arthritis. Here’s my take on select abstracts.